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The concept of multi-target drugs has arisen
studying molecular mechanism of action among
several efficient drugs, such as neuroleptics, antide-
pressants, and antineurodegenerative agents which
affect many targets simultaneously. Moreover, the
pattern of promiscuous drugs is based on the fact
that common central nervous disorders, such as
depression, schizophrenia, Alzheimerís or Parkin-
sonís diseases, and epilepsy, tend to result from
multiple molecular abnormalities, and not from a
single defect. This multi-target strategy has expand-
ed tremendously the number of potential targets and
has led to the introduction of new classes of drugs
with potentially less serious side-effects and lower
toxicity (1, 2). 
An arylpiperazine moiety is one of the most
universal templates used for designing agents active
at G-protein coupled receptors (GPCRs). Simple
arylpiperazines are classified as non-selective recep-
tor ligands, but long-chain arylpiperazines (LCAPs)
have been found to be serotonin receptor ligands, in
particular 5-HT1A and 5-HT2A. Their general chemi-
cal structure contains an alkyl chain (2ñ4 methylene
units) attached to the N4 atom of the piperazine moi-
ety, and a terminal fragment: an amide or imide.
Numerous studies have indicated that even a minor
structural modification within the LCAP ring or at
the terminal fragment (an amide or imide moiety)
strongly affects receptor affinity and selectivity
(3ñ7). For several years, we have been developing
LCAP-class agents completed with an amide ring,
which were evaluated in functional in vivo models
of anxiety and depression (8ñ11). 
Imidazolidine-2,4-dione is an important core
unit that exhibits a range of central and peripheral
biological activities and is incorporated into many
drugs with numerous therapeutic applications (12,
13). Therefore, well-known antiepileptic agents
such as phenytoin, mephenythoin, norantoin,
methetoin, ethotoin, fosphenytoin are based on the
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structure of the imidazolidine-2,4-dione (13).
Moreover, imidazolidine-2,4-dione derivatives can
also be found as antiarrhythmics (azimilide), antimi-
crobial drugs (nitrofurantoin), skeletal muscle relax-
ants (dantrolene) and non-steroidal antiandrogens
(nilutamide), while allantoin (5-ureidohydantoin) is
used as a keratolytic, astringent, wound remedy,
antacid and antipsoriatic drug (13). Imidazolidine-
2,4-dione (hydantoin) can be substituted in several
positions and the search for hydantoin-based drugs
is ongoing. 
In order to obtain compounds acting on multi-
ple biological targets, two pharmacophoric systems
(hydantoin and LCAPs) were combined. Following
the results of our previous study (9, 11), we extend-
ed our studies aimed at verification of the impact of
the linker between spirohydantoin derivatives and
the arylpiperazine moiety. The influence on sero-
tonin and dopamine receptor activity of different
ìspiroî substituents at the 5 position of a hydantoin
moiety was studied. For this reason, we proposed to
introduce an aromatic ring into the ìspiroî sub-
stituent as a flexible (9ñ16) or rigid (17ñ26) frag-
ment. Furthermore, the arylpiperazine fragment was
changed into a 1,2,3,4,-tetrahydroisoquinoline moi-
ety to diversify the affinity of the designed com-
pounds for serotonin receptors. 
In this paper, we report on the synthesis of new
propyl spirohydantoin derivatives and their biologi-
cal evaluation toward monoaminergic receptors (α1,
5-HT1A, 5-HT2A, 5-HT6, 5-HT7, D2, D3) and a sero-
tonin transporter (SERT). We also discuss whether
the proposed modifications will improve affinity for
serotonin and dopamine receptors as well as allow
suitable multi-receptor profile characteristics for
antidepressant or antipsychotic activity to be
achieved. Furthermore, the interactions of com-
pound 19 with 5-HT1A/7 receptors are discussed
based on molecular modeling study results.
EXPERIMENTAL
Chemistry
The structure of the final compounds 9-26 was
established on the basis of the results of elemental
(C, H, N) and spectral (1H NMR, 19F NMR) analyses.
NMR spectra were recorded on Varian Mercury 300
MHz spectrometer (Varian Inc., Palo Alto, CA,
USA); chemical shifts are expressed in parts per
million (ppm), using the solvent (CDCl3 or DMSO-
d6) signal as an internal standard. Signal multiplets
are represented by the following abbreviations: s
(singlet), br s (broad singlet), d (doublet), t (triplet),
m (multiplet). Melting points were determined in
open capillaries on an Electrothermal 9300 appara-
tus and were uncorrected. Thin-layer chromatogra-
phy (TLC) was performed on Merck silica gel 60
F254 aluminium sheets (Merck; Darmstadt, Germa-
ny), using the following mixtures of solvents: (S1)
benzene/ethyl acetate/acetone (10 : 5 : 1, v/v/v) and
(S2) acetone/isopropanol/chloroform (20 : 10 : 1,
v/v/v). Elemental analyses for C, H, N were carried
on an Elementar Vario EL III apparatus (Hanau,
Germany). LC/MS analysis was performed on
Waters Acquity TQD system, with a Waters TQD
quadrupole mass spectrometer with detection by UV
(DAD) using an Acquity UPLC BEH C18 column
(1.7 µm, 2.1 mm ◊ 100 mm). Water/acetonitrile gra-
dient with 0.1% TFA was used as a mobile phase at
a flow rate of 0.3 mL/min. 
The starting spirohydantoins (1ñ4) and inter-
mediate (7, 8) were prepared according to previous-
ly described methods (9, 11).
1-(3-Chloropropyl)-8-phenyl-1,3-diazaspiro [4.5]
decan-2,4-dione (5)
The free base was obtained in 72% yield as
white powder ; m.p. 212ñ214OC; TLC: Rf = 0.56
(S1); Analysis: calcd. for C17H21N2O2Cl: C 63.64, H
6.60, N 8.73%; found: C 63.63, H 6.73, N 8.50%.
1-(3-Chloropropyl)-6-phenyl-1,3-diazaspiro[4.5]
decan-2,4-dione (6)
The free base was obtained in 73% yield as
white powder: yield 73%; m.p. 210ñ211OC; TLC: 
Rf = 0.64 (S1); Analysis: calcd. for C17H21N2O2Cl: C
63.64, H 6.60, N 8.73%; found: C 63.66, H 6.65, N
8.55%.
General procedure for preparing final compounds
9-26
An intermediate 1-(3-chloropropyl)-spirohy-
dantoin (5 mmol) and the substituted 1-phenylpiper-
azine or tetrahydroisoquinoline (10 mmol) in ethyl
(9ñ12, 14, 15, 17ñ26) or butyl (13) alcohol or 2-
methoxyethanol (16) were refluxed for 40 h sepa-
rately. After cooling, the solvent was evaporated and
the residue was extracted with CHCl3 (3 ◊ 15 mL).
The combined organic phases were dried, filtered
off and evaporated. The obtained oily product was
purified either by crystallization from anhydrous
ethanol (comp. 14, 15, 17ñ26) or by column chro-
matography (comp. 9ñ13, 16), using a mixture of
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The free base was obtained in 59% yield as
white powder; m.p. 188ñ190OC; 1H NMR (300 Hz,
CDCl3, δ, ppm): 8.38 (s, 1H), 7.20ñ7.37 (m, 7H),
6.83ñ6.99 (m, 3H), 3.64ñ3.68 (t, 2H, J = 7.20 Hz),
3.17ñ3.20 (t, 4H, J = 4.70 Hz), 2.60ñ2.69 (m, 5H),
2.46ñ2.51 (t, 2H, J = 7.20 Hz), 1.89ñ2.08 (m, 5H),
1.70ñ1.83 (m, 5H). TLC: Rf = 0.07 (S1); 0.74 (S2);
HPLC: Rt = 2.41 (99%); LC/MS (m/z): 447.6 [M +
H]+. Analysis: calcd. for C27H34N4O2 ◊ H2O: C





The free base was obtained in 67% yield as
white powder; m.p. 179ñ181OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 7.65 (br s, 1H), 7.20ñ7.33 (m, 5H),
6.83ñ6.99 (m, 4H), 3.85 (s, 3H), 3.61ñ3.66 (t, 2H, J
= 7.18 Hz), 3.07 (br s, 4H), 2.63 (br s, 5H), 2.44ñ2.48
(t, 2H, J = 7.18 Hz), 1.93ñ2.08 (m, 5H), 1.65ñ1.90
(m, 5H). TLC: Rf = 0.79 (S2); HPLC: Rt = 2.43
(99%). Analysis: calcd. for C28H36N4O3: C 70.56, H
7.61, N 11.76%; found: C 70.42, H 7.65, N 11.55%.
3-{3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl}-
8-phenyl-1,3-diazaspiro[4.5]decan-2,4-dione (11)
The free base was obtained in 55% yield as
white powder; m.p. 197ñ199OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 8.15 (s, 1H), 7.12ñ7.33 (m, 6H),
6.73ñ6.83 (m, 3H), 3.63ñ3.67 (t, 2H, J = 7.00 Hz),
3.20 (br s, 4H), 2.67ñ2.69 (m, 5H), 2.15ñ2.20 (t, 2H,
J = 6.90 Hz), 1.97ñ2.08 (m, 5H), 1.67ñ1.81 (m, 5H).
TLC: Rf = 0.71 (S2); HPLC: Rt = 2.64 (96%).
Analysis: calcd. for C27H33N4O2Cl: C 67.42, H 6.91,




The free base was obtained in 69% yield as
white powder; m.p. 214ñ216OC; 19F NMR (300 Hz,
CDCl3 δ, ppm): -62.72 (s, 3F); 1H NMR (300 Hz,
CDCl3, δ, ppm ): 8.54 (s, 1H), 7.18ñ7.36 (m, 6H),
6.99ñ7.06 (m, 3H), 3.63ñ3.67 (t, 2H, J = 7.30 Hz),
3.18ñ3.21 (t, 4H, J = 4.80 Hz), 2.56ñ2.68 (m, 5H),
2.44ñ2.49 (t, 2H, J = 7.30 Hz), 1.85ñ2.06 (m, 6H),
1.72ñ1.79 (m, 4H). TLC: Rf = 0.73 (S2); HPLC: Rt =
2.76 (97%); LC/MS (m/z) 515.5 [M + H]+.
3-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)propyl]-8-
phenyl-1,3-diazaspiro[4.5]decan-2,4-dione (13)
The free base was obtained in 54% yield as
creamy powder; m.p. 179ñ181OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 1.60ñ1.72 (m, 4H), 1.91ñ2.02 (m,
6H), 2.56ñ2.62 (m, 3H), 2.67ñ2.71 (t, 2H, J = 5.20
Hz), 2.85ñ2.89 (t, 2H, J = 5.20 Hz), 3.59 (s, 2H),
3.65ñ3.69 (t, 2H, J = 7.00 Hz), 6.96ñ7.32 (m, 9H),
7.80 (s, 1H). TLC: Rf = 0.64 (S2); HPLC: Rt = 2.38
(99%). Analysis: calcd. for C26H31N3O2: C 74.79, H
7.48, N 10.06%; found: C 75.00, H 7.48, N 9.98%.
3-[3-(4-Phenylpiperazin-1-yl)propyl]-6-phenyl-
1,3-diazaspiro[4.5]decan-2,4-dione (14)
The free base was obtained in 60% yield as
white powder; m.p. 208ñ209OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 1.14ñ1.28 (m, 2H) 1.42ñ1.58 (m,
3H), 1.76ñ1.91 (m, 5H), 2.04ñ2.09 (t, 2H, J = 7.00
Hz), 2.44ñ2.47 (t 4H, J = 5.00 Hz,), 3.07ñ3.09 (m,
1H), 3.14ñ3.18 (t, 4H, J = 5.00 Hz), 3.21ñ3.26 (t,
2H, J = 7.00 Hz), 6.81ñ7.10 (m, 3H), 7.17ñ7.28 (m,
8H). TLC: Rf = 0.09 (S1); 0.84 (S2); HPLC: Rt = 2.27
(97%); LC/MS (m/z) 447.6 [M+H]+. Analysis:
calcd. for C27H34N4O2: C 72.62, H 7.67, N 12.55%;




The free base was obtained in 60% yield as
white powder; m.p. 183ñ184OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 7.16ñ7.27 (m, 7H), 6.83ñ7.02 (m,
3H), 3.85 (s, 3H), 3.20ñ3.25 (t, 2H, J = 6.80 Hz),
3.11ñ3.13 (m, 1H), 3.05 (br s, 4H), 2.51 (br s, 4H),
2.08ñ2.12 (t, 2H, J = 7.20 Hz), 1.76ñ1.95 (m, 5H),
1.39ñ1.57 (m, 3H), 1.14ñ1.26 (m, 2H). TLC: Rf =
0.13 (S1), 0.77 (S2); HPLC: Rt = 2.25 (98%).
Analysis: calcd. for C28H36N4O3: C 70.56, H 7.61, N
11.76%; found: C 70.31, H 7.58, N 11.51%.
3-{3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl}-
6-phenyl-1,3-diazaspiro[4.5]decan-2,4-dione (16)
The free base was obtained in 54% yield as
white powder; m.p. 149ñ150OC; 1H NMR (300 Hz,
CDCl3 δ, ppm): 7.12ñ7.27 (m, 7H), 6.74ñ6.86 (m,
3H), 3.19ñ3.26 (t, 2H, , J = 7.10 Hz), 3.13ñ3.17 (t,
4H, J = 5.00 Hz), 3.08ñ3.09 (m, 1H), 2.42ñ2.45 (t,
4H, J = 5.00 Hz), 2.03ñ2.08 (t, 2H, J = 7.20 Hz),
1.76ñ1.91 (m, 5H), 1.42ñ1.58 (m, 3H), 1.13ñ1.27 (m,
2H). TLC: Rf = 0.66 (S2); HPLC: Rt = 2.46 (99%).
Analysis: calcd. for C27H33N4O2Cl ◊ H2O: C 64.98, H
7.07, N 11.23%; found: C 65.13, H 7.15, N 11.14%.
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The free base was obtained in 60% yield as
white powder; m.p. 140ñ142OC; 19F NMR (300 Hz,
CDCl3 δ, ppm): -62.76 (s, 3F); 1H NMR (300 Hz,
CDCl3, δ, ppm): 1.82ñ1.91 (q, 2H, , J = 7.15 Hz)
2.18ñ2.28 (m, 1H), 2.40ñ2.45 (t, 2H, J = 7.15 Hz),
2.56ñ2.59 (t, 4H, J = 5 Hz), 2.65ñ2.74 (m, 1H),
2.98ñ3.10 (m, 1H), 3.16ñ3.20 (t, 4H, J = 5 Hz),
3.21ñ3.29 (m, 1H), 3.58ñ3.63 (t, 2H, J = 7.15 Hz),
6.50 (s, 1H), 7.02ñ7.11 (m, 3H), 7.17ñ7.35 (m, 5H).
TLC: Rf = 0.78 (S2); HPLC: Rt = 2.41 (99%);




The free base was obtained in 57% yield as
creamy powder; m.p. 139ñ140OC; H NMR (300 Hz,
CDCl3 δ, ppm): 1.82ñ1.91 (q, 2H, J = 7.15 Hz)
2.18ñ2.31 (m, 1H), 2.65ñ2.77 (t, 2H, J = 7.00 Hz),
2.99ñ3.08 (m, 4H), 3.17ñ3.34 (m, 3H), 3.66ñ3.70 (t,
4H, J = 6.80 Hz), 5.89 (s, 1H), 7.04ñ7.34 (m, 8H).
TLC: Rf = 0.74 (S2); HPLC: Rt = 1.93 (99%).
Analysis: calcd. for C23H25N3O2: C 73.57, H 6.71, N
11.19%; found: C 73.23, H 7.06, N 11.07%.




The free base was obtained in 56% yield as
white powder; m.p. 151ñ153OC; 19F NMR (300 Hz,
CDCl3 δ, ppm): -62.74 (s, 3F); 1H NMR (300 Hz,
CDCl3, δ, ppm): 7.04ñ7.36 (m, 8H), 5.78 (s, 1H),
3.40ñ3.69 (t, 2H, J = 7.15 Hz), 3.21ñ3.24 (t, 4H, J =
5 Hz), 2.84ñ2.90 (m, 2H), 2.59ñ2.62 (t, 4H, J = 5
Hz), 2.45ñ2.49 (t, 2H, J = 7.15 Hz), 2.23ñ2.31 (m,
2H), 1.74ñ2.03 (m, 4H). TLC: Rf = 0.81 (S2); HPLC:




The free base was obtained in 54% yield as
white powder; m.p. 148ñ151OC; H NMR (300 Hz,
CDCl3 δ, ppm): 7.02ñ7.24 (m, 8H), 5.92 (s, 1H),
3.67ñ3.73 (t, 4H, J = 7.00 Hz), 2.91ñ3.01 (m, 4H),
2.82ñ2.86 (t, 4H, J = 6.90 Hz), 2.22ñ2.31 (m, 2H),
1.74ñ1.99 (m, 4H). TLC: Rf = 0.68 (S2); HPLC: Rt =
Table 1. Binding affinity of investigated compounds for serotonin 5-HT1A, 5-HT2A, 5-HT7 and dopaminergic D2 receptors.
Compd.
Ki ± SEM [nM]
5-HT1A 5-HT2A 5-HT7 D2
9 1668 ± 75 20 ± 2 NT >10000
10 132 ± 9 147 ± 12 NT NT
11 5211 ± 268 56 ± 7 NT >10000
12 2280 ± 88 462 ± 34 NT NT
13 >10000 >10000 775 ± 16 NT
14 743 ± 56 320 ± 34 NT NT
15 128 ± 15 570 ± 45 NT NT
16 149 ± 9 284 ± 15 249 ± 12 NT
17 98 ± 16* 30 ± 2* NT >10000
18 49 ± 2* 653 ± 100* NT NT
19 38 ± 1* 53 ± 6* 77 ± 8 >10000
20 24 ± 2 58 ± 7 83 ± 5 NT
21 >10000 >10000 84 ± 7 NT
22 88 ± 21* 25 ± 5* NT 675 ± 82
23 23 ± 5* 284 ± 9* NT 965 ± 6
24 350 ± 123* 35 ± 6* 145 ± 15 1800 ± 300
25 22 ± 2 49 ± 4 146 ± 11 >10000
26 768 ± 54 919 ± 46 172 ± 13 NT
* data taken from (9), NT ñ not tested
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2.02 (99%). Analysis: calcd. for C24H27N3O2 ◊ H2O:
C 70.74, H 7.17, N 10.31%; found: C 70.54, H 6.97,
N 10.25%.
Pharmacology in vitro
Radioligand binding studies with native 5-
HT1A, 5-HT2A, 5-HT7 and D2 receptors (Table 1)
were conducted according to the methods previous-
ly described (5). Briefly: 5-HT1A assays used rat hip-
pocampal membranes, [3H]-8-OH-DPAT (170
Ci/mmol, NEN Chemicals) and 5-HT for non-spe-
cific binding; 5-HT2A assays used rat cortical mem-
branes, [3H]-ketanserin (88.0 Ci/mmol, NEN
Chemicals) and methysergide for nonspecific bind-
ing; 5-HT7 receptor assay was performed using rat
hypothalamic membranes, [3H]-5-CT (34.5 Ci/
mmol; NEN) and 5-HT for non-specific binding and
D2 assays used rat striatial membranes, [3H]-spiper-
one (15.70 Ci/mmol, NEN Chemicals) and buta-
clamol for nonspecific binding. Each compound was
tested in triplicate at 7ñ8 concentrations (10ñ11ñ10ñ4
M). The radioactivity was measured by liquid scin-
tillation counting (Beckman LS 6500 apparatus) in 4
mL scintillation fluid (Akwascynt, BioCare).
Binding isotherms were analyzed by nonlinear
regression (Prism, GraphPad Software Inc., San
Diego, USA), using the Cheng-Prusoff equation to
calculate Ki values. Results were expressed as
means of at least two separate experiments.
The extended in vitro evaluation of selected
compounds (Table 2) was based on the standard
screening procedure (14ñ19). Detailed conditions of
the assays for respective receptors are shown in
Table 3. Briefly, the investigated compounds were
tested in screening assay at two final concentrations
of 1.0 and 0.1 µM. The analyzed sample consisted of
50 µL of working solution of the tested compound,
50 µL of radioligand and 150 µL of a diluted recep-
tor source and were transferred to a 96-well
microplate. The microplate was covered with a seal-
ing tape, mixed and incubated. Reaction mixtures
were filtered on UniFilter 96 GF/C plate and rapid-
ly washed with 200 µL of chilled 50 mM Tris-HCl
buffer (pH 7.0) using vacuum manifold and 96-well
pipettor. The filtered plate was dried and 30 µL liq-
uid scintillator Betaplate Scint was added to each
well. The radioactivity was measured by MicroBeta
TriLux 1450 scintillation counter (PerkinElmer).
Results were expressed as percent inhibition of spe-
cific binding. 
The functional profiles with respect to 5-HT1A
and 5-HT7 receptors were determined at Cerep (Le
Bois líEveque, 86600 Celle LíEvescault, France)
(20). Further methodological details of these studies
are available on the companyís web site (www.
cerep.fr). 
Moreover, the pharmacological studies tow-
ards 5-HT2A were carried out on male Wistar rats
((KRF.(WI).WU), Animal House, Faculty of
Pharmacy, Jagiellonian University Medical College,
KrakÛw) weighing 170ñ350 g. Treatment of labora-
tory animals in the present study was in full accor-
Table 2. The extended in vitro pharmacological results of selected compounds for 5-HT6, 5-HT7, D2, D3, α1 receptors and for serotonin
transporter (SERT).






10-6 10-7 10-6 10-7 10-6 10-7 10-6 10-7 10-6 10-7 10-6 10-7
11 79 37 87 25 13 22 72 21 70 5 14 10
12 63 0 70 15 26 7 89 28 15 14 8 0
13 31 0 51 31 17 15 64 35 21 3 0 0
16 3 0 85 63 17 8 39 4 94 39 7 8
19 7 0 98 88 15 21 22 11 87 60 0 0
20 0 0 94 84 12 23 64 34 72 33 0 19
21 13 0 89 79 0 0 32 22 48 36 11 14
24 33 0 91 76 29 19 38 19 90 64 3 2
25 27 0 93 78 32 19 59 27 69 28 0 5
26 26 0 83 63 4 11 15 15 55 34 13 5
% inhibition of specific binding of reference drugs (10-6/10-7): a Methiothepin (99/99), Serotonin (75/44); b Methiothepin (99/97),
Olanzapine (73/54); c Haloperidol (97/99), Olanzapine (92/64); d Haloperidol (98/99), Olanzapine (90/76); e Phentolamine (100/99),
Amitriptyline (97/82); f Fluoxetine (96/96), Imipramine (96/91) 
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dance with the respective Polish regulations.
All procedures were conducted according to
guidelines of ICLAS (International Council on
Laboratory Animal Science) and approved by
the Local Ethics Committee on Animal
Experimentation. 
Molecular modeling
The homology models of human 5-HT1A
and 5-HT7 serotonin receptors used herein
were generated based on developed and well-
validated method and described in previously
published papers (10, 21, 22). Glide, induced
fit docking, LigPrep and Protein Preparation
Wizard were implemented in Schro®dinger
Suite software, which was licensed for
Jagiellonian University Collegium Medicum.
RESULTS AND DISCUSSION
The designed spirohydantoins (9ñ26)
were synthesized in a multi-step procedure
summarized in Scheme 1. The core spirohy-
dantoins were obtained in a Bucherer-Berg
reaction (1ñ4), following the alkylation at posi-
tion-N3 of a heterocyclic ring (5ñ8) (9, 11).
Then, coupling with differently substituted
phenylpiperazines (9ñ12, 15ñ20, 22ñ25) or
tetrahydroisoquinoline (13, 21, 26) gave the
final compounds 9ñ26 in moderate yields
(52ñ72%). All the final products were obtained
as racemic mixtures and for the further phar-
macological studies they were transformed into
water-soluble hydrochloride salts. 
In accordance with the strategy of the
multi-receptor ligands, the affinity for serotonin
and dopamine receptors and for serotonin trans-
porters was determined (Tables 1, 2).
Generally, the comparison of substituent at 5
position of the hydantoin moiety showed a
noticeable impact on receptor binding proper-
ties. The results show that the fusion of an aro-
matic area with the cycloalkane ring as a rigid
skeleton (17ñ20, 22ñ25) significantly increased
the binding to serotonin 5-HT1A and 5-HT7
receptor sites (Table 1), whereas the introduc-
tion of the phenyl ring to 5-cyclohexane-spiro-
hydantoin as a flexible fragment (9ñ16) result-
ed in a decreased affinity for those receptors. 
Moreover, it seems that also the secondary
amine and the nature of the substituents in
phenyl ring had a crucial impact on the affinity
to the receptors of the tested compounds. The
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almost all selected spirohydantoin derivatives with a
tetralin or indane moiety in the amide part (19ñ21,
24ñ26) showed moderate activity toward 5-HT7
receptors. It seems that this activity toward 5-HT7
receptors is the result of the occurrence in the struc-
ture of both the amide mentioned above and an elec-
tron withdrawing group/atom in the phenylpiper-
azine moiety or tetrahydroisoquinoline fragment.
Moreover, some compounds with an unsubstituted
phenylpiperazine fragment (9, 17, 22) or their coun-
terparts with 3-chloro (11, 19, 24) or 3-trifluromethyl
substituents (20, 25) possessed a moderate-to-high
affinity for 5-HT2A; two of these show high selectiv-
ity for 5-HT2A receptors (9 and 11). Furthermore, the
presence of an indane and tetralin moiety and a
phenylpiperazine fragment in the structure of the
investigated compounds had a positive impact on the
binding at 5-HT1A receptor sites (17ñ20, 22, 23, 25).
The tetrahydroisoquinoline derivatives (13, 21, 26)
showed no affinity for 5-HT1A/2A receptors, but a
moderate affinity for 5-HT7 receptors. 
Additionally, the spirohydantoin derivatives
with a withdrawing group (Cl, CF3) substituted into
a phenylpiperazine moiety or with a tetrahydroiso-
quinoline fragment (11ñ13, 16, 19ñ21, 24ñ25) were
chosen for screening evaluation and their affinity for
dopamine (D2, D3) and adrenergic (α1) receptors and
serotonin transporters (SERT) was determined
(Table 2). In this screening study, all the selected
compounds showed a high-to-moderate affinity for
5-HT7 receptors. However, apart from compound 11
which had weak affinity for 5-HT6 receptors, the
other derivatives were inactive. The tested com-
pounds exhibited a low or no affinity for dopamine
D2 receptors and were practically devoid of any
affinity for SERT. Moreover, compounds contain-
ing a 3-trifluromethylphenylpiperazine fragment
(12, 20 and 25) or a 8-phenyl-cyclohexyl moiety
(11ñ13) demonstrated a moderate affinity for
dopamine D3 receptors, unlike the other spirohydan-
toin derivatives. In this screening test, most of the
potent serotonin receptor ligands revealed a high-to-
moderate affinity for adrenergic α1 receptors. 
For further functional and molecular modeling
studies, one (19) of the two counterparts (19, 20)
which exhibited a sustainable affinity for serotonin
5-HT1A/2A/7 receptors and a moderate affinity for
dopaminergic D3 receptors was chosen as an exam-
ple. Moreover, for functional profile evaluation, the
two compounds (9, 11) with the highest selectivity
and affinity for 5-HT2A receptors were selected.
The binding mode of the lead compound 19 at
the sites of serotonin 5-HT1A and 5-HT7 receptors
was analyzed in detail, as a representative one. To
this end, the previously developed homology mod-
els of the receptors were used (20). The tested com-
pound was synthesized in a racemic form; neverthe-
less, predominantly better scores and more favor-
able interactions in both targets were observed for
the S enantiomer, and therefore its binding mode
was described. The binding mode of the ligand in
the two receptors was shown to be consistent both
with the common one for monoaminergic receptor
ligands and with previous results (20, 23). The com-
pound 19 molecule in the 5-HT1A receptor adopted
linear conformation, extending from the deeper cav-
ity formed by transmembrane helices (TMHs) 3ñ6
to the second interaction pocket located between
TMHs 1, 2 and 7. In the 5-HT7 receptor, the mole-
cule bent to find interactions in less spatial pocket
situated closer to TMH3. The main anchoring inter-
action in both sites was a charge-reinforced hydro-
gen bond between the protonated nitrogen atom of
the ligand and the carboxyl group of Asp3.32, as
well as CH-π interactions of the arylpiperazine and
aromatic amino acid cluster of the deeper cavity,
Scheme 1. Synthetic pathways of compounds 9ñ26. Reagents and conditions: (i) KCN, (NH4)2CO3, 50% ethyl alcohol, 28 h, 56OC; (ii)
K2CO3, KJ, acetone, reflux 20 h (iii), -substituted piperazine derivatives or tetrahydroisoquinoline, 96% ethyl or butyl (compd. 13) alco-
hol or 2-methoxyethanol (compd. 16), reflux 40 h
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mainly Phe6.52 (Fig. 1). The spirohydantoin frag-
ment of the molecule occupied the additional cavity
and found both the hydrophobic and polar, favorable
contacts there, which varied depending on the recep-
tor type. For 5-HT1A receptors, the carbonyl oxygen
of hydantoin formed an h-bond with the NH2 group
of Asn7.39, while the aromatic ring of indane inter-
acted with the phenyl ring of Tyr2.64 (π-π stacking,
Fig. 1A). In the 5-HT7 receptor, the latter fragment
formed an analogous interaction with Phe3.28,
although the conformation seems to be suboptimal,
since the complex lacks additional favorable inter-
actions of h-bond nature (e.g., with Arg7.36), which
may contribute to the relatively lower affinity of
compound 19 for this site (Fig. 1B). On the other
hand, the m-Cl substituent at the phenylpiperazine
fragment is devoid of polar interactions with, for
example, Ser5.42 or Lys191 from the second extra-
cellular loop (ECL), which, if present, might have
increased affinity for 5-HT1A receptors.
On the basis of binding affinity results, com-
pound 19 was selected as an example for functional
in vitro screening toward serotonin 5-HT1A and 5-
HT7 receptors. Compound 19 was classified (Fig. 2)
as an agonist of 5-HT1A receptors (59.5% in 1.0E-06
M) and a weak antagonist of 5-HT7 receptors
(41.1% in 1.0E -06 M). 
The antagonist activity of compounds 9 and 11
toward 5-HT2A-receptors present in rat aorta was
assessed via the inhibition of serotonin-induced con-
tractions (Fig. 3). Both compounds 9 and 11 dis-
played an ability to block the contractions induced by
serotonin, giving a pKB value estimate of 7.665 ±
0.034 and 7.110 ± 0.048, respectively. It is noticeable
that the affinity from the functional tests for the stud-
ied compounds was in the same concentration range
as that determined in the radioligand binding assay.
CONCLUSION 




Figure 1. Binding modes of compound 19 in the binding sites of 5-HT1A (A) and 5-HT7 (B) receptors. Amino acid residues engaged in lig-
and binding (within 4 from the ligand atoms) are shown as thick sticks. Dotted yellow lines represent H-bonds with polar residues. For
the sake of clarity a part of ECL2 was hidden. TMH ñ transmembrane helix; ECL ñ extracellular loop
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diones connected with an arylpiperazine or tetrahy-
droisoquinoline fragment by the propylene carbon
chain, which have proven to be potent serotonin
receptor ligands. The obtained pharmacological
results demonstrated that the introduction of an aro-
matic area into the cycloalkane ring as rigid frag-
ment (indane or tetralin) at position 5 of imidazoli-
dine-2,4-dione noticeably increases the affinity for
serotonin receptors. Moreover, the presence of a
withdrawing group substituted into a phenylpiper-
azine moiety had a positive impact on the binding at
5-HT1A, 5-HT2A, 5-HT7 receptor sites. In contrast,
the replacement of arylpiperazine fragment with
tetrahydroisoquinoline moiety resulted in decreased
affinity for 5-HT1A/2A receptors. Therefore, based on
preliminary pharmacological research, two com-
Figure 2. Functional properties for compound 19, percent of control agonist response (on the top) and percent inhibition of control agonist
response (on the bottom)
Figure 3. Concentration-response curves to serotonin in the rat aorta in the absence (■) or presence of compound 9 (on the left, ▼100 nM);
and 11 (on the right, ▼100 nM); results are expressed as percentage of the maximal response to KCl depolarizing solution. Each point rep-
resents the mean ± SEM (n = 4)
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pounds (19, 20) which possessed high affinity for
serotonin 5-HT1A, 5-HT2A, 5-HT7 receptors and
moderate affinity for dopaminergic D3 receptors
were selected for further pharmacological studies.
Furthermore, interactions with serotonin 5-HT1A/7
were described for compound 19, which behaved as
a 5-HT1A agonist and weak 5-HT7 antagonist.
Additionally, from among the compounds with
multi-receptor profile, we obtained two compounds
(9 and 11) with suboptimal affinity which behave as
antagonists of 5-HT2A receptors. 
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